HFS
CRSP icon

Hughes Financial Services’s CRISPR Therapeutics CRSP Stock Holding History

Hughes Financial Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04K Hold
19
– – ﹤0.01% 911
2026
Q1 		$904 Buy
19
+4
+27% +$211 ﹤0.01% 787
2025
Q4 		$787 Hold
15
– – ﹤0.01% 788
2025
Q3 		$819 Hold
15
– – ﹤0.01% 774
2025
Q2 		$845 Buy
+15
New +$580 ﹤0.01% 741

Other funds holding CRSP

EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Hughes Financial Services's CRSP Position: Q2 2026 in Review

Hughes Financial Services held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 19 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #911.

Hughes Financial Services first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. 109 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Hughes Financial Services held 19 shares of CRISPR Therapeutics worth $1.04K as of Q2 2026.
  • Hughes Financial Services left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Hughes Financial Services's portfolio in Q2 2026, its #911 holding.
  • Hughes Financial Services first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 109 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.